Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Prostate tumor–mediated IFNG signaling primes myeloid cells in bone premetastatic niche for immunosuppressive IL-10 signaling
Mindy K. Graham, Sarki A. Abdulkadir
Mindy K. Graham, Sarki A. Abdulkadir
View: Text | PDF
Research Letter Cell biology Oncology

Prostate tumor–mediated IFNG signaling primes myeloid cells in bone premetastatic niche for immunosuppressive IL-10 signaling

  • Text
  • PDF
Abstract

Authors

Mindy K. Graham, Sarki A. Abdulkadir

×

Figure 1

IFNG signaling is upregulated in bone marrow myeloid cells of the premetastatic niche in patients with prostate cancer.

Options: View larger image (or click on image) Download as PowerPoint
IFNG signaling is upregulated in bone marrow myeloid cells of the premet...
(A) Stacked bar plot showing the percentage composition of cell types in benign (12,400 cells) and premetastatic niche bone marrow (18,259 cells). (B) Scatterplot of myeloid cell fraction of benign bone marrow (N = 7), premetastatic niche bone marrow (N = 8), tumor-adjacent bone marrow (N = 8), and metastatic tumor (N = 9). (C) Hypergeometric test of significantly (P < 0.05) upregulated genes in myeloid cells of the premetastatic niche compared with benign bone marrow. Heatmaps showing (D) IFNG and receptor expression (IFNGR1, IFNGR2) across all cells and (E) IFNG expression of lymphoid cells grouped by tissue type. Scatterplots of average expression of (F) IFNGR1, (G) IL10RA, and (H) IL10 in myeloid cells across bone marrow and metastatic tumor samples. Bars represent mean ± SEM. Cell proportions and differential gene expression analysis were conducted using RAISIN (version 1) to generate log fold-change and P values to determine significance.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts